EdgarLookup

Viking Therapeutics, Inc. — Insider Transactions

Form 4 filings by directors, officers, and 10%+ shareholders

SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.

Overview All Filings Annual Quarterly Insiders
Insider Title Type Shares Price Value Owns After Date
MORNEAU MICHAEL VP, Finance and Administration Tax Withholding 7,616 $4.22 $32,140 94,035 May 4, 2018
Lian Brian President & CEO Tax Withholding 10,086 $4.22 $42,563 1,483,012 May 4, 2018
MORNEAU MICHAEL Chief Financial Officer Award / Grant 15,000 101,651 Jan 19, 2018
Lian Brian President & CEO Award / Grant 40,000 1,493,098 Jan 19, 2018
MORNEAU MICHAEL Chief Financial Officer Tax Withholding 8,192 $1.34 $10,977 80,604 May 4, 2017
FOEHR MATTHEW W Purchase 13,000 $1.21 $15,730 39,250 Nov 15, 2016
Hanley Rochelle Chief Medical Officer Tax Withholding 10,595 $1.31 $13,879 160,836 May 4, 2016
FOEHR MATTHEW W Purchase 20,000 $1.24 $24,800 26,250 Apr 13, 2016
LIGAND PHARMACEUTICALS INC Award / Grant 560,000 5,340,964 Apr 13, 2016
LIGAND PHARMACEUTICALS INC Other 228,105 4,780,964 May 28, 2015
Lian Brian President & CEO C 2,731 1,426,825 May 4, 2015
Dinerman Michael Chief Operating Officer Disposition 998,250 576,750 May 4, 2015
MORNEAU MICHAEL Chief Financial Officer Tax Withholding 10,404 $9.49 $98,734 77,404 May 4, 2015
Hanley Rochelle Chief Medical Officer Award / Grant 70,000 161,547 May 4, 2015
FOEHR MATTHEW W Purchase 6,250 $8.00 $50,000 6,250 May 4, 2015